Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

Manolo Carta, Thomas Carlsson, Ana Muñoz, Deniz Kirik, Anders Björklund

Research output: Contribution to journalArticlepeer-review


Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

Original languageEnglish
Pages (from-to)465-478
Number of pages14
JournalProgress in Brain Research
Publication statusPublished - 2008

Subject classification (UKÄ)

  • Neurosciences

Free keywords

  • Animals
  • Clinical Trials as Topic
  • Dopamine
  • Dyskinesia, Drug-Induced
  • Humans
  • Levodopa
  • Parkinson Disease
  • Parkinsonian Disorders
  • Presynaptic Terminals
  • Protein Isoforms
  • Receptors, Dopamine
  • Receptors, Serotonin
  • Serotonin
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review


Dive into the research topics of 'Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias'. Together they form a unique fingerprint.

Cite this